Germany / Switzerland / Italy / Sweden / Norway / Belgium / France / Austria / United States / Canada / United Kingdom / China / Luxembourg / Finland / Spain / Denmark / /
Currency
CHF / /
Event
FDA Phase / Business Partnership / Funding / Company Listing Change / Product Release / /
IndustryTerm
cancer therapy / cancer therapies / treatment algorithms / pharmaceutical / pharmaceutical product launches / hospital product / pharmaceutical products / biopharmaceutical company developing products / /
MedicalCondition
Pseudomonas / severe bacterial infections / invasive yeast infections / mucormycosis / community-acquired pneumonia / recurrent solid tumors / severe pneumonia / infections / fungal infections / invasive aspergillosis / MRSA pneumonia / pneumonia / conventional cancer / cancer / invasive mucormycosis / bacterial infections / ventilator-associated pneumonia / hospital-acquired pneumonia / solid tumor / severe invasive mold infections / invasive fungal disease / specific infections / diseases / infectious diseases / infection / invasive fungal infections / currently available cancer / Infectious disease / /
MedicalTreatment
ANTIBIOTICS / cancer therapy / cancer therapies / antibiotic therapy / /
Organization
U.S. FDA Anti-Infective Drugs Advisory Committee / American Society of Clinical Oncology / Congress / European Medicines Agency / Biomedical Advanced Research and Development Authority / FDA / U.S. Department of Health and Human Services First / /
Person
DAVID VEITCH / Ronald Scott / Martin Nicklasson / / /
Position
Chief Executive Officer / CHAIRMAN OF THE BOARD AND THE CHIEF EXECUTIVE OFFICER / treating physician / CHIEF COMMERCIAL OFFICER / Chairman of the Board / ’S CHIEF COMMERCIAL OFFICER / /
Product
Zevtera/Mabelio / Authorization Application / vitamin A / Zevtera® (ceftobiprole medocaril) / Prescription Drug / Oncology drug / BAL30072 / ANTIBIOTICS Zevtera ® / BAL101553 / /
pwc_master_logo_shortform